Cargando…
Engineered transcription-associated Cas9 targeting in eukaryotic cells
DNA targeting Class 2 CRISPR-Cas effector nucleases, including the well-studied Cas9 proteins, evolved protospacer-adjacent motif (PAM) and guide RNA interactions that sequentially license their binding and cleavage activities at protospacer target sites. Both interactions are nucleic acid sequence...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541143/ https://www.ncbi.nlm.nih.gov/pubmed/37781609 http://dx.doi.org/10.1101/2023.09.18.558319 |
_version_ | 1785113851459534848 |
---|---|
author | Goldberg, Gregory W. Kogenaru, Manjunatha Keegan, Sarah Haase, Max A. B. Kagermazova, Larisa Arias, Mauricio A. Onyebeke, Kenenna Adams, Samantha Fenyö, David Noyes, Marcus B. Boeke, Jef D. |
author_facet | Goldberg, Gregory W. Kogenaru, Manjunatha Keegan, Sarah Haase, Max A. B. Kagermazova, Larisa Arias, Mauricio A. Onyebeke, Kenenna Adams, Samantha Fenyö, David Noyes, Marcus B. Boeke, Jef D. |
author_sort | Goldberg, Gregory W. |
collection | PubMed |
description | DNA targeting Class 2 CRISPR-Cas effector nucleases, including the well-studied Cas9 proteins, evolved protospacer-adjacent motif (PAM) and guide RNA interactions that sequentially license their binding and cleavage activities at protospacer target sites. Both interactions are nucleic acid sequence specific but function constitutively; thus, they provide intrinsic spatial control over DNA targeting activities but naturally lack temporal control. Here we show that engineered Cas9 fusion proteins which bind to nascent RNAs near a protospacer can facilitate spatiotemporal coupling between transcription and DNA targeting at that protospacer: Transcription-associated Cas9 Targeting (TraCT). Engineered TraCT is enabled when suboptimal PAM interactions limit basal activity in vivo and when one or more nascent RNA substrates are still tethered to the actively transcribing target DNA in cis. We further show that this phenomenon can be exploited for selective editing at one of two identical targets in distinct gene loci, or, in diploid allelic loci that are differentially transcribed. Our work demonstrates that temporal control over Cas9’s targeting activity at specific DNA sites may be engineered without modifying Cas9’s core domains and guide RNA components or their expression levels. More broadly, it establishes RNA binding in cis as a mechanism that can conditionally stimulate CRISPR-Cas DNA targeting in eukaryotes. |
format | Online Article Text |
id | pubmed-10541143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-105411432023-10-01 Engineered transcription-associated Cas9 targeting in eukaryotic cells Goldberg, Gregory W. Kogenaru, Manjunatha Keegan, Sarah Haase, Max A. B. Kagermazova, Larisa Arias, Mauricio A. Onyebeke, Kenenna Adams, Samantha Fenyö, David Noyes, Marcus B. Boeke, Jef D. bioRxiv Article DNA targeting Class 2 CRISPR-Cas effector nucleases, including the well-studied Cas9 proteins, evolved protospacer-adjacent motif (PAM) and guide RNA interactions that sequentially license their binding and cleavage activities at protospacer target sites. Both interactions are nucleic acid sequence specific but function constitutively; thus, they provide intrinsic spatial control over DNA targeting activities but naturally lack temporal control. Here we show that engineered Cas9 fusion proteins which bind to nascent RNAs near a protospacer can facilitate spatiotemporal coupling between transcription and DNA targeting at that protospacer: Transcription-associated Cas9 Targeting (TraCT). Engineered TraCT is enabled when suboptimal PAM interactions limit basal activity in vivo and when one or more nascent RNA substrates are still tethered to the actively transcribing target DNA in cis. We further show that this phenomenon can be exploited for selective editing at one of two identical targets in distinct gene loci, or, in diploid allelic loci that are differentially transcribed. Our work demonstrates that temporal control over Cas9’s targeting activity at specific DNA sites may be engineered without modifying Cas9’s core domains and guide RNA components or their expression levels. More broadly, it establishes RNA binding in cis as a mechanism that can conditionally stimulate CRISPR-Cas DNA targeting in eukaryotes. Cold Spring Harbor Laboratory 2023-09-18 /pmc/articles/PMC10541143/ /pubmed/37781609 http://dx.doi.org/10.1101/2023.09.18.558319 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Goldberg, Gregory W. Kogenaru, Manjunatha Keegan, Sarah Haase, Max A. B. Kagermazova, Larisa Arias, Mauricio A. Onyebeke, Kenenna Adams, Samantha Fenyö, David Noyes, Marcus B. Boeke, Jef D. Engineered transcription-associated Cas9 targeting in eukaryotic cells |
title | Engineered transcription-associated Cas9 targeting in eukaryotic cells |
title_full | Engineered transcription-associated Cas9 targeting in eukaryotic cells |
title_fullStr | Engineered transcription-associated Cas9 targeting in eukaryotic cells |
title_full_unstemmed | Engineered transcription-associated Cas9 targeting in eukaryotic cells |
title_short | Engineered transcription-associated Cas9 targeting in eukaryotic cells |
title_sort | engineered transcription-associated cas9 targeting in eukaryotic cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541143/ https://www.ncbi.nlm.nih.gov/pubmed/37781609 http://dx.doi.org/10.1101/2023.09.18.558319 |
work_keys_str_mv | AT goldberggregoryw engineeredtranscriptionassociatedcas9targetingineukaryoticcells AT kogenarumanjunatha engineeredtranscriptionassociatedcas9targetingineukaryoticcells AT keegansarah engineeredtranscriptionassociatedcas9targetingineukaryoticcells AT haasemaxab engineeredtranscriptionassociatedcas9targetingineukaryoticcells AT kagermazovalarisa engineeredtranscriptionassociatedcas9targetingineukaryoticcells AT ariasmauricioa engineeredtranscriptionassociatedcas9targetingineukaryoticcells AT onyebekekenenna engineeredtranscriptionassociatedcas9targetingineukaryoticcells AT adamssamantha engineeredtranscriptionassociatedcas9targetingineukaryoticcells AT fenyodavid engineeredtranscriptionassociatedcas9targetingineukaryoticcells AT noyesmarcusb engineeredtranscriptionassociatedcas9targetingineukaryoticcells AT boekejefd engineeredtranscriptionassociatedcas9targetingineukaryoticcells |